secwatch.observer — SEC 8-K summary
======================================

Issuer:     Inmune Bio, Inc. (INMB)
CIK:        0001711754
Form:       8-K
Filed at:   2025-06-10T23:59:59+00:00
Accession:  0001213900-25-053051
Event type: other_material
Sentiment:  neutral
Materiality: 0.55
Item codes: 5.02, 5.07, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

INmune Bio shareholders approve share increase to 6.5M; XPro shows amyloid reduction post-TBI
--------------------------------------------------------------------------------

- Stockholders approved Amended 2021 Stock Incentive Plan, increasing shares from 4M to 6.5M; permits accelerated vesting on change of control.
- XPro™ reduced Aβ42, BACE1, and caspase-3 in hippocampus; improved neurological outcomes in transgenic AD mice after TBI.
- Collaboration with Virginia Commonwealth Univ. on TBI-AD link; poster presented at Keystone Symposia on June 10, 2025.
- All director nominees elected; CBIZ CPAs ratified as auditor for FY2025; non-binding say-on-pay and frequency every three years approved.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1711754/000121390025053051/0001213900-25-053051-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1711754/000121390025053051/ea0245174-8k_inmune.htm
  HTML page:      https://secwatch.observer/filing/0001213900-25-053051

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer